Boston Scientific touts real-world data for Emblem’s sensing filter
Boston Scientific (NYSE:BSX) announced results last week from an analysis of a real-world database which evaluated the reduction of inappropriate shocks using the Smart Pass sensing filter in patients with the Emblem subcutaneous implantable defibrillator system.
The study showed that when the sensing filter was in use, the rate of inappropriate shocks dropped to 4.3% after one year.
Boston Scientific’s Smart Pass filter is an algorithm within the Emblem S-ICD that filters out particular signals that cause inappropriate shocks.
After reviewing one year of remote monitoring data from 1,984 patients, researchers found that the Smart Pass filter reduces the risk of the first inappropriate shock by 50% and the risk for all inappropriate shocks by 68% – without impacting the delivery of appropriate shocks.
“The study data validate the clinical benefit of this sensing methodology to significantly reduce inappropriate shocks by the S-ICD,” presenting author Dr. Tom Brouwer said in prepared remarks. “At one year, the inappropriate shock rate for patients with the Smart Pass filter in use was as low as rates observed in studies with transvenous implantable cardioverter-defibrillators employing modern programming strategies.”
“The positive data presented today underscore our commitment to advancing this device and providing protection for patients at risk for sudden cardiac death while avoiding the risks and complications associated with transvenous leads,” Dr. Kenneth Stein, SVP & CMO of Boston Scientific’s global health policy and rhythm management business, added. “We are excited for the future of the S-ICD and results from upcoming clinical trials assessing its value when paired with our forthcoming leadless pacemaker as part of a modular device system.”